2023
October
AACR Tumor Immunology and Immunotherapy Meeting 2023
October 25, 2023
This week’s extensive special feature covers select talks from the AACR Tumor Immunology and Immunotherapy Meeting 2023 in Toronto, Canada. We have organized the content by topics below. Keynote lectureCrystal Mackall T cell therapiesPhil GreenbergCarl JuneGreg Delgoffe Cytokine therapiesPablo UmanaIvana DjureticDavid Brooks Tumor immune microenvironmentCatherine J. WuThomas GajewskiPaul ThomasRobert Schreiber Immune regulationMatthew KrummelPing-Chih...
A new marching order for the T cell army in the attack of AML
October 18, 2023
Acute myeloid leukemia (AML) is the most frequent leukemia in adults. Currently, allogeneic hematopoietic stem cell transplantation, although associated with high risks for relapse, transplant-related morbidity, and graft-versus-host disease, is the only curative treatment option. At present, CAR T cell therapies targeting myeloid cell surface antigens that are overexpressed in AML, but are...
TIM-3 blockade offers new hope for incurable childhood cancer, DIPG
October 11, 2023
Mainly due to its location in the pons, a part of the brainstem that controls many of the body's vital functions, and its infiltrative nature, diffuse intrinsic pontine glioma (DIPG) is one of the most devastating and challenging childhood cancers. Currently, oncologists can only offer radiotherapy to stabilize the tumor and reduce symptoms...
Improving CAR T cell activity by removing CTLA-4
October 4, 2023
Despite major successes with CD19-directed CAR T cell therapy in various hematological malignancies, not all patients respond. Given that CAR T cells (CART) upregulate immune checkpoint molecules, and that combination treatment with immune checkpoint blockade can enhance responses, Agarwal et al. assessed whether deletion of CTLA-4 and/or PD-1 from CAR T cells could...
